Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Flatiron Health's Evidence Solutions provide a versatile method for generating real-world evidence, both prospective and retrospective, which aids life sciences companies in efficiently meeting their oncology research objectives. At the heart of these offerings is Flatiron Horizon, a comprehensive platform that combines a rich database of more than 5 million anonymized patient records and 1.5 billion data points, coupled with advanced curation techniques and disease-specific machine learning models. This innovative platform is designed to facilitate various phases of the biopharma lifecycle, including discovery, clinical study design, regulatory submissions, and post-marketing commitments. Furthermore, Flatiron's services deliver customized real-world data configurations that cater specifically to oncology, enabling prospective evidence generation through minimally invasive studies and optimizing protocols for better patient identification. Additionally, the platform ensures a streamlined transfer of data from electronic health records to electronic data capture systems with the functionality of Flatiron Clinical Pipe, enhancing overall research efficiency and effectiveness. Such capabilities position Flatiron Health as a leader in transforming oncology research through the power of real-world data.
Description
Specialty and rare diseases often encompass patient populations that are not clearly defined, including individuals who remain undiagnosed or face misdiagnoses, along with healthcare providers who may lack knowledge about these conditions and their various manifestations, resulting in treatment pathways that are poorly understood. IPM.ai operates as an Insights-as-a-Service (IaaS) firm, dedicated to empowering leading life sciences organizations to gain deeper insights into patient care and enhance the quality of life for those affected through the development, clinical research, and commercialization of therapeutic solutions. By predicting market size, analyzing the competitive landscape, and estimating potential return on investment, companies can optimize their commercialization strategies. Additionally, the platform identifies undiagnosed and misdiagnosed individuals who could benefit from early disease interception and therapeutic measures. It employs statistical models to gauge the prevalence of specific diseases within certain patient populations at any given moment. Furthermore, IPM.ai helps pinpoint physicians who are adept at diagnosing and treating these ideal patients, while also influencing other healthcare providers to enhance overall patient outcomes. This comprehensive approach ultimately aims to bridge the gap in understanding and addressing the needs of those with rare diseases.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
Flatiron
Country
United States
Website
flatiron.com/real-world-evidence
Vendor Details
Company Name
IPM.ai
Country
United States
Website
www.ipm.ai/platform